Opinions are my own and not the views of my employer

Miami, FL
Joined August 2022
Dr. Mercedes Prudencio and Dr. Leonard Petrucelli have identified an abnormal RNA marker that may help explain why Alzheimer’s disease progresses faster in some people. Higher levels of abnormal UNC13A RNA were linked to greater cognitive impairment and faster decline, offering a potential new way to track disease progression and a target for future therapies. 🧠 Learn more: loom.ly/uFKMNCU
2
3
402
Check out our new study! rdcu.be/fzOMO
1
2
445
PrudencioLab retweeted
A team of NIH-funded researchers shed new light on how short RNA molecules prevent abnormal clumping of the TDP-43 protein. These findings, in cell and animal models, suggest RNA-based therapies could one day be used to treat diseases like ALS and Alzheimer’s disease. Learn more: bit.ly/43YLRtc
12
28
3
90
11,225
TDP-43 subtypes shape transcriptomic signatures in Alzheimer's disease biorxiv.org/content/10.64898… @PrudencioLab Excited to share our new transcryptomics study in AD where we use quantiative measures of pathological pTDP-43 and pTau to discern changes resulting from each pathology.
7
28
2,368
Dr. Timothy Miller, 2023 Rainwater Prize winner and Tau Consortium member, leads this @JAMANeuro article reporting long‑term Phase 3 and open‑label extension results in SOD1-ALS. Catch up on this example of bold, patient-focused science: jamanetwork.com/journals/jam…
2
5
321
PrudencioLab retweeted
Predictive Cellular Signatures from Live Human Motor Neurons Distinguish TDP-43 ALS and Enable ALS Subtype Stratification: biorxiv.org/content/10.64898… – at Philadelphia, PA
4
5
1,184
PrudencioLab retweeted
Loss of progranulin drives the buildup of TMEM106B fibrils in lysosomes, causing their membranes to burst. Risk variants in TMEM106B accelerate this process. @UMich @univmiami @NIH @Stanford ow.ly/tW0b50YTw2W
4
12
1,206
Dr. Leonard Petrucelli has joined the Miller School of Medicine as Founding Director of the Neuroscience Institute. Dr. Petrucelli is a visionary scientist and a global leader in neurodegeneration research. His seminal work has uncovered the molecular mechanisms underpinning Alzheimer’s disease, frontotemporal dementia and ALS. His research reveals novel biomarkers and therapeutic targets that will help shape the next generation of treatments, helping to improve the lives of patients facing these devastating diseases. Welcome, Dr. Petrucelli! Read more: loom.ly/xQNlf4M
1
9
36
3,150
The MBI community gathered today to honor longtime colleague Dr. David Borchelt. Dr. Gopal Thinakaran, a close collaborator of Borchelt's, opened the First Annual David R. Borchelt Excellence in Neurodegeneration Research Seminar with a talk on BIN1’s role in Alzheimer’s.
2
4
10
534
PrudencioLab retweeted
Tracking #ALS early could transform care. Target ALS-backed scientists are developing blood & CSF tests for #CrypticPeptides—potential early biomarkers. Learn more: bit.ly/45vb0wc #ALSResearch #EveryoneLives
1
1
14
402
Dr. Leonard Petrucelli is a globally recognized leader in neurodegeneration and our longtime Scientific Advisor. He's been instrumental in shaping #ALSResearch and the very foundation of Target ALS. As he steps down from his role with us, we celebrate his partnership and vision.
1
2
6
861
PrudencioLab retweeted
Join us in celebrating our 2024 Cozzarelli Prize Class IV: Biomedical Sciences winning paper, “Ultrahigh frequencies of peripherally matured LGI1- and CASPR2-reactive B cells characterize the cerebrospinal fluid in autoimmune encephalitis.” Read more: ow.ly/SyAL50VyXLV
3
2
9
3,003